MedTrace Logo

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-03-14

No results posted yet for this study

Summary

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

Conditions

  • Alopecia, Androgenetic

Interventions

DRUG

TDM-105795

TDM-105795 topical solution

DRUG

Placebo

Placebo for TDM-105795 topical solution

Sponsors & Collaborators

  • Therapeutics, Inc.

    collaborator INDUSTRY

  • Technoderma Medicines Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel Piacquadio, M.D. · Therapeutics Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-11-15
Completion
2023-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05244980 on ClinicalTrials.gov